Published in Oncoimmunology on October 01, 2012
BCG immunotherapy for bladder cancer--the effects of substrain differences. Nat Rev Urol (2013) 1.60
Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology (2014) 0.96
Immunological basis in the pathogenesis and treatment of bladder cancer. Expert Rev Clin Immunol (2014) 0.83
Future directions in bladder cancer immunotherapy: towards adaptive immunity. Immunotherapy (2016) 0.77
Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer. Oncotarget (2016) 0.76
Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol (2001) 25.63
Cytokines and Immune Response in the Tumor Microenvironment. J Immunother (1991) (2001) 1.59
Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother (2007) 1.25
IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy. J Immunol (1999) 1.22
Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guérin. J Immunol (1999) 1.15
Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity. Clin Exp Immunol (2003) 1.12
IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol (2002) 1.11
Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol (2002) 1.06
Treatment options for BCG failures. World J Urol (2006) 0.94